Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Open Label Phase II Trial of FDG-PET-Guided Metastasis Directed Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer: PRTY Trial: PET- Guided Radiotherapy Consolidation

NCT06244004 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT06244004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06244004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Open Label Phase II Trial of FDG-PET-Guided Metastasis Directed Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer: PRTY Trial: PET- Guided Radiotherapy Consolidation
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Recruiting
Start date
February 18, 2024
Completion date
February 18, 2028
Enrollment
125 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

castration-sensitive prostate carcinoma, metastatic prostate carcinoma, stage ivb prostate cancer ajcc v8